Increased incidence, survival, and registration quality of primary hepato-pancreato-biliary cancers in the Netherlands Cancer Registry

荷兰癌症登记处原发性肝胆胰肿瘤的发病率、生存率和登记质量均有所提高

阅读:2

Abstract

Given the poor survival and relatively poor performance of hepato-pancreato-biliary (HPB) cancers on data quality indicators for cancer registries, we assessed trends in incidence, survival, and data quality of HPB cancers within the Netherlands Cancer Registry (NCR). All primary solid liver, gallbladder, biliary tract, and pancreatic cancers (topography C22-23-24-25) diagnosed between 1989 and 2022 were included (n = 109,552). Cancer mortality data were obtained from Statistics Netherlands. For incidence and mortality, revised European Age-Standardised Rates, and for survival, age-standardised 5-year relative survival (AS-5yRS) were calculated. Over time, incidence rates increased for liver (males: 3.0 to 8.2/100,000; females 1.2 to 3.9/100,000), pancreatic (males: 15.8 to 18.5/100,000; females: 11.1 to 15.3/100,000), and biliary tract cancers in males (3.9 to 4.9/100,000; not females: 3.3 to 2.9/100,000). Gallbladder cancer incidence decreased until 2005 (males: 1.5 to 0.8/100,000, females 4.0 to 1.5/100,000). Mortality trends mirrored incidence patterns, with smaller increases. AS-5yRS improved across all HPB cancers with the largest increase in liver (males: 3.4% to 20.8%; females: 6.7% to 18.3%) and pancreatic cancers (males: 2.3% to 10.4%; females: 3.5% to 11.3%). Since 2010, survival gains for gallbladder (males: 8.4% to 16.3%; females: 12.2% to 15.8%) and biliary tract cancers (males: 11.7% to 19.1%; females: 10.7% to 15.6%) have stagnated. Mortality-to-Incidence ratios versus 5-year relative survival for liver and pancreatic cancers improved toward equilibrium. Data quality improved (e.g., autopsy, unspecified morphology) or remained stable (multiple primaries). Both incidence and survival rates of primary HPB cancers have increased over time. Increased completeness of incidence data was attributed to changed notification sources.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。